UNSPSC 51372109: Oxymorphone

This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9VXA968E0C, chemically known as 3,14-dihydroxy-4,5-alpha-epoxy-17-methylmorphinan-6-one but generally known as oxymorphone, which bears US NIH Compound Identifier 5284604. European Medicines Agency schedules Oxymorphone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09569MIG. The term OXYMORPHONE is an International Non-Proprietary Name.

UNSPSC 51372109 Oxymorphone is a Commodity code for pharmaceutical products, though recent state and local procurement activity under this code focuses primarily on naloxone procurement, therapeutic pharmacy program implementation, and multi-source generic pharmaceutical distribution rather than oxymorphone specifically. State and local governments are buying naloxone through competitive bid processes, exploring direct-to-manufacturer prescription programs to improve cost management and fulfillment efficiency, and procuring generic pharmaceuticals through cooperative purchasing alliances. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations administering agreements for multiple participating jurisdictions. These procurement vehicles range from individual competitive bids for specific naloxone quantities to exploratory RFIs for future pharmacy benefit program design and multi-award RFPs for generic product distribution across state and local facilities.

Recent activity spans Florida and Texas, with broader reach through Minnesota's MMCAP cooperative purchasing agreement covering multiple states including Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery through July 26, 2023 (response date); the procurement requires electronic bid submission and includes a two-year initial term with one-year renewal option. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would bypass traditional pharmacy benefit managers and wholesalers, with the RFI serving as market intelligence to inform future RFP development. Minnesota's MMCAP issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multi-award contracts for generic and OTC pharmaceuticals distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with products available by May 15, 2026, and contract effectiveness July 1, 2026.